SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results …
Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in the third quarter of 2023, relative to $4 million in …
MIDLAND, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Diamondback Stockholders, This letter is meant to be a supplement to our earnings release and is being furnished to the Securities and Exchange Commission (SEC) and released to our stockholders …
SaaS Subscription Revenue(1) grew 15% year-over-year to $29.4 million Reports second consecutive quarter of positive cash flows from operating activities and Adjusted Operating Loss(2) well ahead of guidance Coveo Relevance Generative Answering™ general …
Les revenus tirés des abonnements SaaS (1)ont augmenté de 15% par rapport à l’année précédente à 29,4 M$US Deuxième trimestre consécutif de flux de trésorerie provenant des activités d'exploitation positifs et d’une perte d'exploitation ajustée(2) …
SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, reported today financial results for the three and nine months ended …
FORT WORTH, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended September 30, 2023. Highlights Third Quarter 2023 Sales volumes, …
OAK RIDGE, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Lakeland Bancorp, Inc. (NASDAQ: LBAI) (the “Company”), the parent company of Lakeland Bank, today announced that the Company’s 2023 Annual Meeting of Shareholders (“Annual Meeting”) will be held virtually …
MIDLAND, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback” or the “Company”) today announced financial and operating results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTS Average …
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an …
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m …
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be …
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target to support further development of VTX958 in psoriasis; …
Delivers Strong Revenue with Adjusted EBITDA Ahead of Guidance Raises 2023 Guidance Third quarter revenue of $119 million, up 13% year over year Third quarter GAAP net income (loss) of ($18) million Third quarter Adjusted EBITDA of ($4) million Updating …
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., …
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40 …
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble …
MIDLAND, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Viper Energy Partners LP (NASDAQ:VNOM) (“Viper” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the third …
National data champions recognized during govDATAx on November 7th for contributions to evidence-informed decisionmaking and data policy WASHINGTON, DC, USA, November 6, 2023 /EINPresswire.com/ -- The Data Foundation today announced that five …
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of …
07 days 14:34:52
